SCHEMBL1241500

SCHEMBL1241500

O=C(O)C(=O)N(Cc1ccc(F)cc1)c1ccc(-c2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.82

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 11/20 0.82
LTB4R2 Q9NPC1 1/20 0.46
PPARA Q07869 1/20 0.45
CYP2C8 P10632 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
GLP1R P43220 1/20 0.42
GCGR P47871 1/20 0.42
GIPR P48546 1/20 0.42
PTGIR P43119 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1239730 0.95 SERPINE1 (0.90) SERPINE1PPARANR1H4GLP1RGCGR
SCHEMBL1241400 0.91 SERPINE1 (0.93) SERPINE1LTB4R2NR1H4GLP1RGCGR
SCHEMBL1242512 0.91 SERPINE1 (0.93) SERPINE1LTB4R2NR1H4GLP1RGCGR
SCHEMBL1242665 0.90 SERPINE1 (0.82) SERPINE1LTB4R2NR1H4GLP1RGCGR
SCHEMBL1239623 0.90 SERPINE1 (1.00) SERPINE1NR1H4
SCHEMBL1239836 0.89 SERPINE1 (0.81) SERPINE1GLP1RGCGRGIPR
SCHEMBL1241371 0.89 SERPINE1 (0.80) SERPINE1PTGDR2NR1H4
SCHEMBL1242125 0.89 SERPINE1 (0.80) SERPINE1LTB4R2NR1H4
SCHEMBL4009362 0.89 SERPINE1 (0.80) SERPINE1PTGDR2NR1H4GCGRGIPR
SCHEMBL1239486 0.88 SERPINE1 (0.78) SERPINE1PTGDR2NR1H4GCGRGIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 US disclosed
EP-2072498-A1 N-PHENYLOXAMIDIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-06-24 EP disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885LTB4R2 1577/4885PPARA 1341/4885
US-20090215899-A9 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885LTB4R2 1577/4885PPARA 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.